Epitope Platform

A novel multi-epitope peptide vaccine

Developing a synthetic peptide epitope multicomponent vaccine that induces the formation of neutralizing antibodies to four serotypes of dengue virus, and does not contribute to strengthening antibody-dependent infection.

  • Developed within the framework of epitope vaccine for the prevention of dengue fever consists of a mixture of peptide immunogens mimicking the neutralizing epitopes of the virus coat protein E of 4 types of dengue virus serotypes.

  • Methods of epitope technology are to be used for the design of peptide immunogens that accumulates in a single set of methods of bioinformatics, molecular immunology, viruses’ molecular biology and peptide chemistry.

  • The structure of the synthetic peptides designed to exclude the presence of elements responsible for the development of an immunopathological state – of antibody-dependent infection strengthening.

  • Synthetic peptides mimic only functionally significant fragments of the coat protein, which are able to induce the formation of neutralizing antibodies only.

  • Virus-specific antibodies are not able to neutralize the virus, but are capable of inducing antibody-dependent enhancement of infection after immunization with the peptide vaccine, which is a unique advantage of the peptide vaccine compared with all the vaccines in which the E protein of dengue virus is present.

  • Another advantage of peptide vaccines is their synthetic nature; peptide antigens are developed in a few days on the automatic peptide synthesizer, which allows producing a new synthetic antigen without the participation of living biosystem-producers.

Epitope technology has been successfully used to create a peptide vaccine against Ebola that successfully passed the second phase of clinical trials at the end of 2016.